"Nov. 20, 2012 -- Oral contraceptives should be made available without a prescription to reduce unintended pregnancies, according to a newly published opinion by the American College of Obstetricians and Gynecologists (ACOG).
(norethindrone and ethinyl estradiol) Tablets, Chewable and Ferrous Fumarate Tablets 0.4mg/35mcg
Ferrous fumarate tablets are not USP for dissolution and assay.
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
- Patient Information:
Details with Side Effects
FEMCON® Fe (norethindrone and ethinyl estradiol tablets) provides a regimen for oral contraception derived from 21 white tablets composed of norethindrone and ethinyl estradiol followed by 7 brown ferrous fumarate (placebo) tablets. The chemical name for norethindrone is 17-hydroxy-19-nor-17a-pregn-4-en-20-yn-3-one and for ethinyl estradiol the chemical name is 19-nor-17a-pregna-1,3,5(10)-trien-20-yne-3,17-diol. The structural formulas are:
The active white FEMCON Fe (norethindrone and ethinyl estradiol tablets) tablets contain 0.4 mg norethindrone and 0.035 mg ethinyl estradiol, and the following inactive ingredients: dibasic calcium phosphate, lactose, magnesium stearate, maltodextrin, povidone, sodium starch glycolate, spearmint flavor and sucralose.
The brown tablets contain ferrous fumarate, microcrystalline cellulose, magnesium stereate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
Last reviewed on RxList: 1/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Femcon Fe Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.